# Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients

Study · id `cardio:ct-nct07173855` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07173855](<https://clinicaltrials.gov/study/NCT07173855>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07173855

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3853 participants.

## Technical summary

Registry record NCT07173855. Randomized; no masking; primary purpose treatment. Start 2025-11-25 (actual); primary completion 2027-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3853 participants (planned count; ClinicalTrials.gov record NCT07173855, source copy `cardio:ctgov-nct07173855-2026-11-17`, retrieved 2026-11-18)
- Started: 2025-11-25 (actual) (ClinicalTrials.gov record NCT07173855, source copy `cardio:ctgov-nct07173855-2026-11-17`, retrieved 2026-11-18)
- Primary completion: 2027-03-01 (anticipated) (ClinicalTrials.gov record NCT07173855, source copy `cardio:ctgov-nct07173855-2026-11-17`, retrieved 2026-11-18)
- Completion: 2027-06-01 (anticipated) (ClinicalTrials.gov record NCT07173855, source copy `cardio:ctgov-nct07173855-2026-11-17`, retrieved 2026-11-18)
- Countries: Canada (ClinicalTrials.gov record NCT07173855, source copy `cardio:ctgov-nct07173855-2026-11-17`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07173855-2026-11-17`, retrieved 2026-11-18)

## The registry's words

- Brief title: Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
- Acronym: MAGNOLIA
- Condition: Critical Illness
- Intervention (Drug): Magnesium sulfate administration
- Intervention (Drug): Magnesium oxide
- Intervention (Drug): Magnesium glucoheptonate
- Lead sponsor: Scarborough General Hospital
- Lead sponsor class: OTHER
- Collaborator: Scarborough Health Network
- Collaborator class: OTHER
- Collaborator: Lakeridge Health Corporation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Scarborough General Hospital (`cardio:org-scarborough-general-hospital`)

## Provenance

Content hash: a7553aef0616a41088f63ee846c166f2fac695682fa01ad7c5be362f6e3ac728
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
